These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 20858186)

  • 1. Managing bleeding complications in patients treated with the old and the new anticoagulants.
    Romualdi E; Rancan E; Siragusa S; Ageno W
    Curr Pharm Des; 2010; 16(31):3478-82. PubMed ID: 20858186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bleeding with dabigatran, rivaroxaban, apixaban. No antidote, and little clinical experience.
    Prescrire Int; 2013 Jun; 22(139):155-9. PubMed ID: 23866358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How I treat target-specific oral anticoagulant-associated bleeding.
    Siegal DM; Garcia DA; Crowther MA
    Blood; 2014 Feb; 123(8):1152-8. PubMed ID: 24385535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylaxis of venous thromboembolism: low molecular weight heparin compared to the selective anticoagulants rivaroxaban, dabigatran and fondaparinux.
    Welzel D; Hull R; Fareed J
    Int Angiol; 2011 Jun; 30(3):199-211. PubMed ID: 21617603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban.
    Fawole A; Daw HA; Crowther MA
    Cleve Clin J Med; 2013 Jul; 80(7):443-51. PubMed ID: 23821689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New anticoagulants: how to deal with treatment failure and bleeding complications.
    Kazmi RS; Lwaleed BA
    Br J Clin Pharmacol; 2011 Oct; 72(4):593-603. PubMed ID: 21752066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct thrombin and factor Xa inhibitors in children: a quest for new anticoagulants for children.
    Streif W; Ageno W
    Wien Med Wochenschr; 2011 Feb; 161(3-4):73-9. PubMed ID: 21404143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical pharmacological aspects of new oral anticoagulants].
    Haschke M
    Ther Umsch; 2012 Nov; 69(11):657-60. PubMed ID: 23117669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bleeding and antidotes in new oral anticoagulants.
    Majeed A; Schulman S
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):191-202. PubMed ID: 23953907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of switching from vitamin K antagonists to dabigatran or rivaroxaban in daily care--results from the Dresden NOAC registry.
    Beyer-Westendorf J; Gelbricht V; Förster K; Ebertz F; Röllig D; Schreier T; Tittl L; Thieme C; Hänsel U; Köhler C; Werth S; Kuhlisch E; Stange T; Röder I; Weiss N
    Br J Clin Pharmacol; 2014 Oct; 78(4):908-17. PubMed ID: 24697922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [From heparin to apixaban: anticoagulants cut both ways?].
    Hartung K; Meyer F; Bock F; Isermann B
    Zentralbl Chir; 2014 Feb; 139(1):89-97. PubMed ID: 23460104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prophylaxis of thromboembolism in atrial fibrillation: new oral anticoagulants and left atrial appendage closure].
    Zeus T; Kelm M; Bode C
    Dtsch Med Wochenschr; 2015 Aug; 140(16):1213-5. PubMed ID: 26261929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013.
    Pernod G; Albaladejo P; Godier A; Samama CM; Susen S; Gruel Y; Blais N; Fontana P; Cohen A; Llau JV; Rosencher N; Schved JF; de Maistre E; Samama MM; Mismetti P; Sié P;
    Arch Cardiovasc Dis; 2013; 106(6-7):382-93. PubMed ID: 23810130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New anticoagulants--are we prepared?].
    Pawlikowska Z; Szponar J
    Przegl Lek; 2012; 69(8):483-5. PubMed ID: 23243913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis.
    Gómez-Outes A; Terleira-Fernández AI; Lecumberri R; Suárez-Gea ML; Vargas-Castrillón E
    Thromb Res; 2014 Oct; 134(4):774-82. PubMed ID: 25037495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New approaches to reversing oral anticoagulant therapy. Introduction.
    Nutescu EA
    Am J Health Syst Pharm; 2013 May; 70(10 Suppl 1):S1-2. PubMed ID: 23640527
    [No Abstract]   [Full Text] [Related]  

  • 17. Managing bleeding in anticoagulated patients in the emergency care setting.
    Pollack CV
    J Emerg Med; 2013 Sep; 45(3):467-77. PubMed ID: 23786779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of the bleeding patient receiving new oral anticoagulants: a role for prothrombin complex concentrates.
    Baumann Kreuziger LM; Keenan JC; Morton CT; Dries DJ
    Biomed Res Int; 2014; 2014():583794. PubMed ID: 25136597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
    Mantha S; Ansell J
    Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW; Barillari G
    J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.